Pharmaceuticals
Soligenix Inc. Receives FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease
Soligenix Inc. has been granted FDA orphan drug designation for dusquetide, a significant step forward in treating Behçet’s Disease, highlighting the potential for new therapies in rare diseases.
Fifty 1 Labs and BioSpark AI Pioneer AI-Driven Drug Repurposing with Major Database Achievement
Fifty 1 Labs and BioSpark AI have created a structured database from over 10,000 case reports, marking a significant advancement in AI-driven drug repurposing for complex conditions.
CNS Pharmaceuticals Inc. to Showcase Innovative Cancer Treatments at Webull Financial Biotech/MedTech Webinar
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) will present its groundbreaking cancer treatment research at the upcoming Webull Financial Corporate Connect Webinar Series, highlighting the potential of its drug candidate TPI 287 in treating brain and central nervous system cancers.
Soligenix Inc. Reports Q2 2025 Results with Progress in Rare Disease Treatments
Soligenix Inc. highlights advancements in its rare disease treatment pipeline, including progress in psoriasis and cutaneous T-cell lymphoma therapies, amidst a widened net loss in Q2 2025.
CNS Pharmaceuticals Inc. Advances TPI 287 Toward Phase 2 GBM Trial Amid Improved Financials
CNS Pharmaceuticals Inc. reports a slight improvement in Q2 2025 financials, with reduced net losses and increased R&D expenses as it prepares for a Phase 2 trial of TPI 287 for glioblastoma multiforme, highlighting the drug's potential to cross the blood-brain barrier and treat CNS tumors.
Alpha Cognition Inc. Advances Alzheimer's Treatment with ZUNVEYL, Secures Key Regulatory Milestones
Alpha Cognition Inc. reports significant progress in the commercialization of ZUNVEYL for Alzheimer's disease, highlighting early adoption in the U.S. long-term care market and a key regulatory achievement in China.
Public Health Groups Alert New York to Counterfeit HIV Medication Crisis
Public health organizations have filed a complaint against a New York pharmacy for allegedly dispensing counterfeit HIV medication, posing a severe risk to patients and public health.
Nutriband Inc. CEO Temporarily Steps Down to Pursue Irish Presidency, Company Focuses on AVERSA Fentanyl Development
Nutriband Inc. announces CEO Gareth Sheridan's temporary departure to run for Irish Presidency, with Chairman Serguei Melnik stepping in, as the company advances its AVERSA Fentanyl abuse-deterrent opioid patch towards FDA approval.
Alliance Global Partners Raises Soligenix Inc. Price Target Amid Clinical Progress
Alliance Global Partners has increased Soligenix Inc.'s price target to $10 per share, citing advancements in its clinical programs for rare diseases.
Quantum BioPharma Ltd. Advances MS Treatment with CDMO Agreement for Lucid-MS
Quantum BioPharma Ltd. has taken a significant step towards clinical trials for its oral Lucid-MS treatment for multiple sclerosis by partnering with a leading contract development and manufacturing organization.
Creative Biolabs Introduces AI-Powered Solution to Revolutionize Drug Discovery
Creative Biolabs has launched an AI-powered end-to-end drug discovery solution aimed at addressing the challenges of high costs, failure rates, and lengthy timelines in drug R&D.
Nutriband Inc. Advances Toward FDA Approval for AVERSA(TM) Fentanyl Abuse-Deterrent Patch
Nutriband Inc. has secured a Type C Meeting with the FDA for its AVERSA(TM) Fentanyl patch, a significant step towards introducing the world's first abuse-deterrent opioid patch to the market.
BioKey Positions Itself as a Strategic U.S. Pharmaceutical Platform Amid Global Tariff Shifts
ABVC BioPharma's subsidiary, BioKey, leverages its Silicon Valley manufacturing facility to meet global demand for compliant drug production, highlighting the importance of local infrastructure in the face of increasing tariffs and supply chain realignments.
Annovis Bio Inc. Secures Comprehensive Patent Coverage for Buntanetap, Enhancing Treatment Prospects for Neurodegenerative Diseases
Annovis Bio Inc. has expanded its patent portfolio to cover a new crystalline form of buntanetap, promising improved stability and bioequivalence for treating neurodegenerative diseases like Alzheimer's and Parkinson's, with protection extending through 2046.
Nutriband Inc. Pioneers Abuse-Deterrent Technology in Response to Opioid Crisis
Nutriband Inc. is advancing its Aversa(TM) technology to combat the misuse of potent opioids like fentanyl, addressing a critical challenge in drug delivery and public health.
Quantum BioPharma Ltd. Reports Positive Phase 1 Safety Results for Lucid-MS
Quantum BioPharma Ltd. announces positive Phase 1 safety results for Lucid-MS, a potential treatment for multiple sclerosis, marking a significant step towards efficacy trials and FDA application.
Soligenix Inc. Advances in Rare Disease Therapeutics with HyBryte(TM) Platform
Soligenix Inc. (NASDAQ: SNGX) is making significant strides in the development of treatments for rare diseases, particularly with its HyBryte(TM) platform for cutaneous T-cell lymphoma, addressing a critical need for FDA-approved therapies in an underserved market.
XOMA Royalty to Acquire LAVA Therapeutics in a Deal Worth Up to $1.24 Per Share Plus Contingent Value Rights
XOMA Royalty Corporation's acquisition of LAVA Therapeutics for up to $1.24 per share plus contingent value rights marks a significant move in the biotech sector, promising to benefit shareholders and advance innovative cancer treatments.
D. Boral Capital LLC Facilitates $22 Million Offering for Omeros Corporation
D. Boral Capital LLC's role as the exclusive placement agent in Omeros Corporation's $22 million registered direct offering highlights the firm's pivotal position in facilitating significant financial transactions for emerging growth companies.
Soligenix Inc. Achieves Significant Milestone in Phase 2a Study for Behçet’s Disease Treatment
Soligenix Inc. reports promising results from its Phase 2a study of SGX945 for Behçet’s Disease, showing potential to address unmet medical needs in inflammatory conditions.
NanoViricides' NV-387 Emerges as Potential Breakthrough in Combatting Measles Outbreaks
NanoViricides Inc. announces its drug candidate NV-387 could significantly impact the treatment of measles, addressing a critical gap in antiviral medications amid rising global outbreaks.
Suboxone Tooth Decay Litigation Update: Key Developments and What They Mean for Plaintiffs
The article discusses the latest developments in the Suboxone tooth decay litigation, highlighting procedural milestones and the implications for plaintiffs seeking justice against Indivior.
Scinai Immunotherapeutics Ltd. Announces Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has published peer-reviewed data in the Journal of Dermatological Treatment, highlighting PC111's potential as a disease modifier for pemphigus and SJS/TEN, offering a new, non-immunosuppressive treatment approach.
Creative Biolabs Advances Single-Domain Antibody Solutions to Meet Therapeutic Demands
Creative Biolabs is enhancing the development of single-domain antibodies (sdAbs), offering innovative solutions for oncology, neurology, and infectious diseases, highlighting their potential to revolutionize treatment approaches.
Fifty 1 Labs to Host Virtual Shareholder Teleconference Featuring Nobel Laureate Dr. James Orbinski
Fifty 1 Labs announces a virtual shareholder teleconference to discuss its strategic roadmap, including AI-driven drug repurposing and significant R&D investments, highlighting its commitment to innovation in health and wellness.
Lexaria's DehydraTECH-Semaglutide Shows Promising Reduction in Side Effects Compared to Rybelsus®
Lexaria Bioscience Corp. reports interim results from its Phase 1b study, showing DehydraTECH-semaglutide significantly reduces gastrointestinal and overall side effects compared to Rybelsus®, potentially improving patient adherence to treatment.
Phlow Corp. Secures $37 Million in Series C Funding to Enhance U.S. Pharmaceutical Supply Chain
Phlow Corp.'s recent $37 million Series C funding round, led by Align Private Capital, underscores its commitment to addressing critical shortages in essential medicines and advancing U.S.-based pharmaceutical manufacturing.
Soligenix Inc. Advances Treatment for Rare Behçet’s Disease with SGX945
Soligenix Inc. is developing SGX945, a promising treatment for Behçet’s disease, addressing the critical need for more effective therapies for this rare condition.
Nutriband Inc. Advances Abuse-Deterrent Drug Delivery with AVERSA Technology
Nutriband Inc. is pioneering in the development of abuse-deterrent transdermal patches, aiming to address critical public health needs with its AVERSA Fentanyl and Buprenorphine candidates.
SASMAR Pharma Strengthens Market Position with Acquisition of Goodwin Nutrition Srl and Moringa Boost Brand
SASMAR Pharmaceuticals' acquisition of Goodwin Nutrition Srl and its Moringa Boost brand signifies a strategic expansion in the health and wellness sector, aiming to meet growing consumer demand for high-quality nutritional supplements.